哪里想瘦打哪里！FDA批准Kythera注射药物股票在即

你才双下巴，你妻儿都双下巴！是非文静之心人皆有之。如果说赘肉是每一个希望具备完美身材的“妹纸”或“汉纸”的背叛，那么一个人情味十足的双下巴称得上是这些人的世间仇敌了。每一分钟，世界性都有人为自己的一张大饼脸而不已自觉，虽然具备一个肉感十足的双下巴捏跟着是挺有肉感的，但是还是有很多人的心理素质使其无法太重一个双下巴之重。您可千万别笑，这甚至仍然成百上千一个庞大的市场需求。根据美国毛发手术协会的实地调查研究工作表明，68%的澳大利亚人对自己的双下巴坚称了“灰心”之情。而有鉴于，最近KytheraCorporation向FDA提交了其专供粉碎双下巴的美容注射的设计药品ATX-101。这种药品进行了许多“胖纸”梦寐以求的功能，哪里想瘦打哪里，称得上是定点减肥。不要以为这种近乎任性的药品只是一个笑话，在FDA下属的毛发和眼科药品专员会的无记名投票中，专家学者可是以17：0的超高票数一致赞同其上市。或许是因为这些专家学者中也有很多饱受双下巴之苦吧。FDA也将计划于今年的5月13日之前对其重申最后最终。如果一切顺利的话，KytheraCorporation计划于今年下半年将该产品上市，分析人士预计这一药品的产值将超过3亿美元之多。随着美容药品市场需求的日趋增加，KytheraCorporation称得上是下了一步好棋。Corporation于往年以8400万美元的价钱从其前携手伙伴海因手中收回了这种药品的全部权利。而KytheraCorporation也希望以此为契机在美容药品市场需求中攻城拔寨。就在上个月，KytheraCorporation和ActelionCorporation达成价值2700万美元的携手协约，共同开发一种失败过的促病变药品，而这种药品被认为有可能开发出一种病患脱发的药品。详细英文报道：Kythera ($KYTH) won the unanimous support of an FDA advisory panel for its fat-busting injection, rolling toward approval with a first-of-its-kind treatment.The agency's independent Dermatologic and Ophthalmic Drugs Advisory Committee voted 17-0 that the drug's benefits outweighed its risks for patients looking to reduce submental fat, or double chin. The FDA is not required to follow its panels' votes, though it most commonly does, and the agency has promised to make a final decision on the injection by May 13. If all goes according to plan, Kythera plans to launch the drug, ATX-101, in the second half of this year.The biotech's shares he more than tripled since it pulled off a $73 million IPO in 2012, rising steadily as investors bet ATX-101 can carve out a space on the aesthetic market and potentially lure a Big Pharma acquirer. Kythera is pitching the injection as a much-needed nonsurgical option for double chin reduction, citing an American Society for Dermatologic Surgery survey that estimates 68% of Americans are "bothered" by submental fat.Kythera regained full rights to ATX-101's potential last year, orchestrating an $84 million deal to buy out ex-partner Bayer. And the drug, a synthetic version of the fat-blasting deoxycholic acid, could bring in more than $300 million a year once approved, Leerink yst Seamus Fernandez has said."This milestone demonstrates our commitment to developing first-in-class aesthetic products through a focus on scientific rigor and innovation," Kythera CEO Keith Leonard said in a statement. "At Kythera, we remain focused on investing in novel treatments that will allow aesthetic physicians to better meet the needs of their patients."Kythera is also focused on raising some cash now that it has a likely approval ahead. The biotech filed for a $125 million offering as soon as the market closed on Monday. Its share price was down several points at the end of the day.Beyond its top prospect, Kythera is working to build out a pipeline of aesthetic medicines. Last month, the California biotech signed a $27 million deal with Actelion ($ATLN) to get its hands on a once-failed anti-inflammatory medicine that could he a future as a treatment for hair loss.